CP
ACAD icon

CenterBook Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

CenterBook Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
68,928
+49,192
+249% +$1.08M 0.09% 259
2026
Q1 		$439K Buy
+19,736
New +$472K 0.02% 510
2025
Q4 		– Sell
-11,152
Closed -$238K – 543
2025
Q3 		$238K Buy
+11,152
New +$264K 0.01% 533

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CenterBook Partners's ACAD Position: Q2 2026 in Review

CenterBook Partners increased its Acadia Pharmaceuticals (ACAD) stake by 249% in Q2 2026, buying an estimated $1.08M and bringing the position to 68,928 shares worth $1.74M. The position accounts for 0.09% of the portfolio, ranked #259.

CenterBook Partners first reported a position in ACAD in Q3 2025 and has held it in 3 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • CenterBook Partners held 68,928 shares of Acadia Pharmaceuticals worth $1.74M as of Q2 2026.
  • CenterBook Partners bought 49,192 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.08M.
  • Acadia Pharmaceuticals made up 0.09% of CenterBook Partners's portfolio in Q2 2026, its #259 holding.
  • CenterBook Partners first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.